---
title: News, Events & Resources | Crystal Bio Solutions | Case Study
description: Case Study | News, events, case studies and more - stay in touch with all the exciting progress at Crystal Bio Solutions.
---

![Crystal Bio Solutions logo](https://www.crystalbiosolutions.com/hs-fs/hubfs/Crystal%20Bio%20Solutions%20logo.webp?width=330&height=150&name=Crystal%20Bio%20Solutions%20logo.webp)

- Bioanalysis & Biomarkers 
    - [All Bioanalysis & Biomarker Services](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [PK Assays for Biologics & ADCs](https://www.crystalbiosolutions.com/services/pk-bioanalysis)
    - [NAb & ADA Immunogenicity Assays](https://www.crystalbiosolutions.com/ada-and-nab-testing-in-biologics-pk-efficacy-and-regulatory-risk)
    - [Receptor Occupancy Assays](https://www.crystalbiosolutions.com/services/receptor-occupancy-assays)
- Biologics CMC Analytical 
    - [All Biologics CMC Analytical Services](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Developability Assessment](https://www.crystalbiosolutions.com/services/biologics-developability-assessment)
    - [Extended Characterization by HRMS](https://www.crystalbiosolutions.com/services/biologics-extended-characterization-hrms)
    - [Biotransformation & In Vivo CQA](https://www.crystalbiosolutions.com/services/biotransformation-in-vivo-cqa)
- [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
- Solutions 
    - [ADC Programs](https://www.crystalbiosolutions.com/antibody-drug-conjugates-adc)
    - [Regulatory Affairs Support](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)

- [Resources](https://www.crystalbiosolutions.com/news-and-events)
- [Case Studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study)
- [About Us](https://www.crystalbiosolutions.com/about-us)
- [Locations](https://www.crystalbiosolutions.com/locations)
- [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Request a Proposal](https://www.crystalbiosolutions.com/contact-us)

![Two scientists reviewing a document together](https://www.crystalbiosolutions.com/hs-fs/hubfs/website-assets/experts-collaborating-at-crystal-bio-solutions.png?width=960&height=640&name=experts-collaborating-at-crystal-bio-solutions.png)

# News, events, and resources

Scientific articles, case studies, events and company news from Crystal Bio Solutions.

All

Scientific Articles

Case Studies

News & Events

Nov 22, 2026

![Crystal Bio Solutions laboratory](https://www.crystalbiosolutions.com/hs-fs/hubfs/CBS%20lab/DSCF0117-min.jpg?width=320&height=240&name=DSCF0117-min.jpg) Scientific Publications by Crystal Bio Solutions Scientists Peer-reviewed publications by Crystal Bio Solutions scientists in bioanalysis, biomarkers, ADC characterization, and clinical pharmacology.

Nov 22, 2026

![Scientist reviewing pharmacokinetic modeling data](https://www.crystalbiosolutions.com/hs-fs/hubfs/AI-Generated%20Media/Images/Modern%20Lab%20Research%20with%20Pharmacokinetic%20Data%20Analysis.png?width=320&height=240&name=Modern%20Lab%20Research%20with%20Pharmacokinetic%20Data%20Analysis.png) Choosing Checkpoint Inhibitor Combinations Before the Trial: What QSP Modeling Adds How quantitative systems pharmacology (QSP) models use existing clinical data to compare checkpoint inhibitor combinations and sequences ...

Nov 22, 2026

![Researcher examining drug vials in a lab](https://www.crystalbiosolutions.com/hs-fs/hubfs/AI-Generated%20Media/Images/Researcher%20Analyzing%20Colorful%20Drug%20Vials%20In%20Sophisticated%20Lab.png?width=320&height=240&name=Researcher%20Analyzing%20Colorful%20Drug%20Vials%20In%20Sophisticated%20Lab.png) Pediatric Dosing With Little Pediatric Data: How Population PK and Exposure-Response Simulation Fill the Gap How population PK, allometric scaling, and exposure-response simulation can support pediatric dose selection when pediatric data are ...

Nov 22, 2026

![Structure of an antibody-drug conjugate](https://www.crystalbiosolutions.com/hs-fs/hubfs/ADC%20structure.png?width=320&height=240&name=ADC%20structure.png) FDA's Clinical Pharmacology Guidance for ADCs: What to Plan From First-in-Human Onward FDA's 2024 clinical pharmacology guidance for ADCs: which analytes to measure from first-in-human, dosing, exposure-response, organ ...

Nov 22, 2026

![Scientist analyzing ADC samples in the lab](https://www.crystalbiosolutions.com/hs-fs/hubfs/AI-Generated%20Media/Images/ADC%20Research%20Lab%20Analysis%20with%20Scientist%20and%20Advanced%20Equipment.png?width=320&height=240&name=ADC%20Research%20Lab%20Analysis%20with%20Scientist%20and%20Advanced%20Equipment.png) Bispecific ADCs: Can 1 + 1 Be Greater Than 2? How bispecific antibody-drug conjugates aim to improve ADC selectivity, internalization, and resistance, and the design challenges early ...

Nov 22, 2026

![Crystal Bio Solutions laboratory](https://www.crystalbiosolutions.com/hs-fs/hubfs/CBS%20lab/DSCF0117-min.jpg?width=320&height=240&name=DSCF0117-min.jpg) NK Cell Engagers: Next-Generation Immunotherapy and What Their Clinical Development Requires How NK cell engagers work, what early DF1001 data showed in HER2-expressing solid tumors, and key considerations for dose selection and ...

Nov 22, 2026

![Two scientists reviewing a document together](https://www.crystalbiosolutions.com/hs-fs/hubfs/website-assets/experts-collaborating-at-crystal-bio-solutions.png?width=320&height=240&name=experts-collaborating-at-crystal-bio-solutions.png) Regulatory Meetings with FDA, EMA, and China's CDE: A Side-by-Side Guide How formal meetings with FDA, EMA, and China's CDE compare: meeting types, when to request them, scheduling timelines, and fees.

Nov 22, 2026

![Immunogenicity assay testing](https://www.crystalbiosolutions.com/hs-fs/hubfs/nab-ada-immunogenicity-crystalbiosolutions.png?width=320&height=240&name=nab-ada-immunogenicity-crystalbiosolutions.png) Immunogenicity Risk Assessment for Biologics: Prediction, Detection, Mitigation, and Reporting A practical overview of immunogenicity risk for biologics: predicting risk, detecting ADA and NAb, setting cut points, managing clinical ...

Nov 22, 2026

![Inspecting a microplate for a cell-based assay](https://www.crystalbiosolutions.com/hs-fs/hubfs/Microplate%20Inspection%20for%20Customized%20Assay%20Analysis.webp?width=320&height=240&name=Microplate%20Inspection%20for%20Customized%20Assay%20Analysis.webp) In Vitro Cytokine Release Assays: Formats, Interpretation, and Limits How in vitro cytokine release assays (CRA) support first-in-human safety for immunomodulatory biologics: formats, readouts, controls, and ...

Nov 22, 2026

![Crystal Bio Solutions](https://www.crystalbiosolutions.com/hs-fs/hubfs/crystal-biosolutions.png?width=320&height=240&name=crystal-biosolutions.png) Integrated Summary of Immunogenicity (ISI): What It Contains and Why It Matters What an Integrated Summary of Immunogenicity (ISI) contains, where it sits in the CTD, and why starting it early helps biologics reach ...

Nov 21, 2026

![Scientist examining a sample in a laboratory](https://www.crystalbiosolutions.com/hs-fs/hubfs/Microplate%20Inspection%20for%20Customized%20Assay%20Analysis.webp?width=320&height=240&name=Microplate%20Inspection%20for%20Customized%20Assay%20Analysis.webp) Cell-Based NAb Assay Development: Choosing the Format and Managing Interference How to choose between cell-based and competitive ligand-binding NAb assays, design a cell-based NAb assay, and manage drug and matrix ...

Nov 21, 2026

![HPLC autosampler in the Crystal Bio Solutions laboratory](https://www.crystalbiosolutions.com/hs-fs/hubfs/CBS%20lab/DSCF0117-min.jpg?width=320&height=240&name=DSCF0117-min.jpg) Biosimilar Analytical Similarity by HRMS: What the Package Should Contain What a monoclonal antibody biosimilar's comparative analytical assessment should include, and where HRMS fits: structure, PTMs, glycans and ...

Nov 21, 2026

![LC-MS/MS system used for hybrid bioanalysis](https://www.crystalbiosolutions.com/hs-fs/hubfs/943fa2104ad62217d9c39af32900dc180e7b419feef8d39248e49151f55efcd6.jpg?width=320&height=240&name=943fa2104ad62217d9c39af32900dc180e7b419feef8d39248e49151f55efcd6.jpg) Hybrid LC-MS/MS for Large Molecule and ADC Bioanalysis When to choose hybrid (immunocapture) LC-MS/MS over a ligand-binding assay for antibody, bispecific and ADC PK, and how the method is built ...

Nov 21, 2026

![ADA and NAb immunogenicity assessment diagram](https://www.crystalbiosolutions.com/hs-fs/hubfs/nab-ada-immunogenicity-crystalbiosolutions.png?width=320&height=240&name=nab-ada-immunogenicity-crystalbiosolutions.png) NAb Assay Qualification vs. Validation: What Each Stage Requires How NAb assay development, qualification and validation differ: format choice, cut points, sensitivity, drug tolerance and what FDA and EMA ...

Oct 14, 2026

![Clinical Dose Optimization: From Phase 2 Dose Finding to FDA Project Optimus](https://www.crystalbiosolutions.com/hs-fs/hubfs/AI-Generated%20Media/Images/Researcher%20Analyzing%20Colorful%20Drug%20Vials%20In%20Sophisticated%20Lab.png?width=320&height=240&name=Researcher%20Analyzing%20Colorful%20Drug%20Vials%20In%20Sophisticated%20Lab.png) Clinical Dose Optimization: From Phase 2 Dose Finding to FDA Project Optimus Explore how PK–PD biomarkers, exposure–response modeling and fit-for-purpose bioanalysis support clinical dose optimization and FDA Project ...

Oct 12, 2026

![18th Annual Immunogenicity & Bioassay Summit](https://www.crystalbiosolutions.com/hs-fs/hubfs/AAPS%20%281126%20x%201126%20px%29%20%283%29.png?width=320&height=240&name=AAPS%20%281126%20x%201126%20px%29%20%283%29.png) 18th Annual Immunogenicity & Bioassay Summit Visit Crystal Bio Solutions at Booth #4, 18th Annual Immunogenicity & Bioassay Summit, to explore partnerships that advance biologics ...

Sep 14, 2026

![How to Choose a CRO for ADC Bioanalysis](https://www.crystalbiosolutions.com/hs-fs/hubfs/AI-Generated%20Media/Images/Modern%20Lab%20Analyzing%20ADCs%20with%20Mass%20Spectrometer%20and%20Data%20Visualizations.png?width=320&height=240&name=Modern%20Lab%20Analyzing%20ADCs%20with%20Mass%20Spectrometer%20and%20Data%20Visualizations.png) How to Choose a CRO for ADC Bioanalysis A checklist for choosing a bioanalytical CRO for ADC and PK studies: analyte coverage, LBA and LC-MS/MS platforms, GLP/GCLP status, and ...

Sep 9, 2026

![Meet CBS at OCT Southern California 2026](https://www.crystalbiosolutions.com/hs-fs/hubfs/Website%20Event%20Cover-SCal%20OCT%20%202026-1.png?width=320&height=240&name=Website%20Event%20Cover-SCal%20OCT%20%202026-1.png) Meet CBS at OCT Southern California 2026 Meet the Crystal Bio Solutions bioanalysis, biomarker and clinical pharmacology team at OCT Southern California 2026, Booth #67b.

Aug 19, 2026

![Crystal Bio Solutions Scientific Symposium & Reception](https://www.crystalbiosolutions.com/hs-fs/hubfs/e58a70bc-953e-4dbb-9df6-06c3e5ffbd2b-1.png?width=320&height=240&name=e58a70bc-953e-4dbb-9df6-06c3e5ffbd2b-1.png) Crystal Bio Solutions Scientific Symposium & Reception The CBS Scientific Symposium & Reception took place on October 13, 2026 in South San Francisco, with talks on bioanalysis, biomarkers ...

Jul 28, 2026

![Population PK/PD Modeling That Starts With Better Bioanalysis](https://www.crystalbiosolutions.com/hs-fs/hubfs/AI-Generated%20Media/Images/Modern%20Lab%20Research%20with%20Pharmacokinetic%20Data%20Analysis.png?width=320&height=240&name=Modern%20Lab%20Research%20with%20Pharmacokinetic%20Data%20Analysis.png) Population PK/PD Modeling That Starts With Better Bioanalysis Discover how integrated bioanalysis, biomarkers, ADA assessment and Pop PK/PD modeling support Model-Informed Drug Development and biologic ...

Jul 14, 2026

![Diagram of a cysteine-conjugated IgG1 antibody-drug conjugate and its critical quality attributes: DAR distribution, unconjugated antibody (D0), free payload, aggregates and fragments, and charge variants](https://www.crystalbiosolutions.com/hs-fs/hubfs/website-assets/cbs-adc-critical-quality-attributes-diagram.png?width=320&height=240&name=cbs-adc-critical-quality-attributes-diagram.png) Critical Quality Attributes in Antibody-Drug Conjugates Learn the six critical quality attributes (CQAs) every ADC program should monitor and how analytical characterization supports successful ...

Jun 10, 2026

![ADC Bioanalysis: DAR Profiling and Stability Analysis](https://www.crystalbiosolutions.com/hs-fs/hubfs/AI-Generated%20Media/Images/ADC%20Research%20Lab%20Analysis%20with%20Scientist%20and%20Advanced%20Equipment.png?width=320&height=240&name=ADC%20Research%20Lab%20Analysis%20with%20Scientist%20and%20Advanced%20Equipment.png) ADC Bioanalysis: DAR Profiling and Stability Analysis Explore key strategies for ADC bioanalysis, including DAR characterization, payload stability, and LC-MS-based biotransformation studies.

Jun 3, 2026

![Heading to BIO International Convention 2026 in San Diego?](https://www.crystalbiosolutions.com/hs-fs/hubfs/CBS%20at%20BIO%202026.jpg?width=320&height=240&name=CBS%20at%20BIO%202026.jpg) Heading to BIO International Convention 2026 in San Diego? Connect with Crystal Bio Solutions in San Diego to optimize your assay strategy, biomarkers, and regulatory compliance.

Jun 2, 2026

![High-Resolution Mass Spectrometry (HRMS) in Biologics Characterization](https://www.crystalbiosolutions.com/hs-fs/hubfs/HRMS_1.png?width=320&height=240&name=HRMS_1.png) High-Resolution Mass Spectrometry (HRMS) in Biologics Characterization Discover how high-resolution mass spectrometry enhances biologics characterization, supporting critical analyses from peptide mapping to ...

Mar 23, 2026

![Antibody Glycosylation by Crystal Bio Solutions](https://www.crystalbiosolutions.com/hs-fs/hubfs/Antibody-Glycosylation-Crystal-Biosolutions.png?width=320&height=240&name=Antibody-Glycosylation-Crystal-Biosolutions.png) Antibody Glycosylation: FDA Requirements and Characterization Fc glycosylation controls antibody efficacy and safety. Learn what FDA expects for characterization, manufacturing and biosimilar ...

Feb 16, 2026

![San Diego Biotech Networking Event 2026: CMC and Development Discussions](https://www.crystalbiosolutions.com/hs-fs/hubfs/San%20Diego.png?width=320&height=240&name=San%20Diego.png) San Diego Biotech Networking Event 2026: CMC and Development Discussions Join Crystal Bio Solutions in San Diego for an informal biotech networking evening focused on CMC, bioanalysis and development strategy.

Feb 16, 2026

![Monoclonal Antibody Biosimilar Drug](https://www.crystalbiosolutions.com/hs-fs/hubfs/Biosimilar-drug-antibody-crystal-bio-solutions.png?width=320&height=240&name=Biosimilar-drug-antibody-crystal-bio-solutions.png) What Does the FDA Require to Approve a Monoclonal Antibody Biosimilar in 2026? What does the FDA require to approve a monoclonal antibody biosimilar in 2026? Analytical, PK, clinical, and immunogenicity evidence ...

Feb 4, 2026

![Common analytical gaps in biosimilar drugs](https://www.crystalbiosolutions.com/hs-fs/hubfs/Common%20analytical%20gaps%20in%20biosimilar%20drugs.png?width=320&height=240&name=Common%20analytical%20gaps%20in%20biosimilar%20drugs.png) The 6 Most Common Analytical Gaps in Biosimilar Programs (and How to Fix Them) Learn the six most common analytical gaps in biosimilar development, why regulators flag them, and how to fix them early to reduce ...

Feb 3, 2026

![Ye Gu and Billy Wu at Crystal Bio Solutions booth at WCBP](https://www.crystalbiosolutions.com/hs-fs/hubfs/Ye-Gu-Billy-Wu-Crystal-Bio-Solutions.jpg?width=320&height=240&name=Ye-Gu-Billy-Wu-Crystal-Bio-Solutions.jpg) WCBP 2026: Why Comparability Is a Challenge for Late-Stage Biopharma WCBP 2026 highlights why comparability is now the key late-stage challenge, from analytical CQA assessment to regulatory expectations and ...

Jan 12, 2026

![Allan Cortes, new head of west coast business development at Crystal Bio Solutions](https://www.crystalbiosolutions.com/hs-fs/hubfs/crystal-biosolutions.png?width=320&height=240&name=crystal-biosolutions.png) Allan Cortes Joins CBS as Head of West Coast Business Development Allan Cortes joins Crystal Bio Solutions as Head of West Coast Business Development, bringing biotech and CRO business development ...

Dec 22, 2025

![Crystal Bio Solutions at WCBP 2026 Washington](https://www.crystalbiosolutions.com/hs-fs/hubfs/Crystal%20Bio%20Solutions%20at%20WCBP%202026%20Washington.jpg?width=320&height=240&name=Crystal%20Bio%20Solutions%20at%20WCBP%202026%20Washington.jpg) Meet Us at WCBP 2026: All Symposium Details Included Crystal Bio Solutions exhibited at WCBP 2026. What WCBP is, who attends, and why it matters for biologics CMC and analytical development.

Dec 15, 2025

![Overview of D0 species in ADCs](https://www.crystalbiosolutions.com/hs-fs/hubfs/Illustration%20of%20D0%20competing%20with%20ADC.png?width=320&height=240&name=Illustration%20of%20D0%20competing%20with%20ADC.png) Critical Quality Attribute D0 Impact in ADC Modality Overview of D0 species in ADCs, compete for target binding, reduce ADC potency, and how they are characterized analytically in development.

Nov 21, 2025

![Antibody Drug Conjugate](https://www.crystalbiosolutions.com/hs-fs/hubfs/Thumbnail-Crystal-Bio-Solutions.png?width=320&height=240&name=Thumbnail-Crystal-Bio-Solutions.png) Strategies for Antibody-Drug Conjugate Bioanalysis ADC bioanalysis must track the antibody, the payload and drug-to-antibody ratio changes in vivo. An overview of the two main analytical ...

Oct 9, 2025

![Case Study: Improving NAb Assay Sensitivity and Drug Tolerance by Optimizing MRD](https://www.crystalbiosolutions.com/hs-fs/hubfs/CS%20-%20Blog%20%20Thumbnail-2.png?width=320&height=240&name=CS%20-%20Blog%20%20Thumbnail-2.png) Improving NAb Assay Sensitivity and Drug Tolerance by Optimizing MRD Case study: changing the minimal required dilution from 1:4 to 1:2 in a competitive ligand-binding NAb assay improved sensitivity 4-fold ...

Sep 18, 2025

![Case Study: Representative Pooled Matrix Selection is Critical in ADA Assays](https://www.crystalbiosolutions.com/hs-fs/hubfs/6.png?width=320&height=240&name=6.png) Representative Pooled Matrix Selection Is Critical in ADA Assays Case study: switching to a pooled matrix representative of the individual study lots changed the ADA screening cut point from 1.03 to 1.11 ...

Sep 18, 2025

![A Generic LC-MS/MS Solution for ADC PK Bioanalysis](https://www.crystalbiosolutions.com/hs-fs/hubfs/LC-MS-MS-ADC-PK-Bioanalysis.png?width=320&height=240&name=LC-MS-MS-ADC-PK-Bioanalysis.png) A Generic LC-MS/MS Solution for ADC PK Bioanalysis Case study: a generic LC-MS/MS workflow quantifying total antibody, conjugated payload and free payload for ADC PK studies, with ...

Sep 18, 2025

![Case Study: An immunogenicity analysis strategy to reduce the interference of soluble target proteins](https://www.crystalbiosolutions.com/hs-fs/hubfs/9.png?width=320&height=240&name=9.png) An Immunogenicity Analysis Strategy to Reduce Interference from Soluble Target Proteins Case study: a target-specific blocking antibody removed false-positive ADA signals caused by soluble drug target in four of five serum ...

Sep 18, 2025

![Case Study: Receptor occupancy of antibody drug measured by FACS](https://www.crystalbiosolutions.com/hs-fs/hubfs/7.png?width=320&height=240&name=7.png) Receptor Occupancy of an Antibody Drug Measured by Flow Cytometry Case study: a flow cytometry PD-1 receptor occupancy assay in the occupied format with total receptor normalization, CV below 8% and 3-day ...

Sep 17, 2025

![Dr. Lorin K. Roskos Appointed Chief Scientific Officer and Head of Quantitative Clinical Pharmacology](https://www.crystalbiosolutions.com/hs-fs/hubfs/Dr-Loris-Roskos-CSO-Crystal-Bio-Solutions.png?width=320&height=240&name=Dr-Loris-Roskos-CSO-Crystal-Bio-Solutions.png) Dr. Lorin K. Roskos Appointed Chief Scientific Officer and Head of Quantitative Clinical Pharmacology Dr. Lorin K. Roskos joins Crystal Bio Solutions as Chief Scientific Officer and Head of Quantitative Clinical Pharmacology, with 30+ years ...

Sep 16, 2025

![A LC-MS/MS Method for Oligonucleotide PK Bioanalysis](https://www.crystalbiosolutions.com/hs-fs/hubfs/LC-MSMS-Oligonucleotide-PK-Bioanalysis.png?width=320&height=240&name=LC-MSMS-Oligonucleotide-PK-Bioanalysis.png) An LC-MS/MS Method for Oligonucleotide PK Bioanalysis Case study: a validated ion-pair LC-MS/MS method for oligonucleotide PK bioanalysis (2.00–2000 ng/mL, about 4.1 min per sample), applied in ...

Sep 16, 2025

![Case Study: Immunophenotyping to identify peripheral lymphocyte subsets](https://www.crystalbiosolutions.com/hs-fs/hubfs/4-1.png?width=320&height=240&name=4-1.png) Immunophenotyping to Identify Peripheral Lymphocyte Subsets Case study: a validated flow cytometry method that identifies CD4 and CD8 T-cell subsets and five NK-cell subsets to support clinical ...

Sep 16, 2025

![Crystal Bio Solution Case Study](https://www.crystalbiosolutions.com/hs-fs/hubfs/Improve-Drug-Tolerance-ADA-Assay.png?width=320&height=240&name=Improve-Drug-Tolerance-ADA-Assay.png) Sample Pretreatment Approaches to Improve Drug Tolerance in ADA Assays Case study: adding an acid dissociation–affinity capture step raised ADA assay drug tolerance to at least 8 µg/mL of drug at 100 ng/mL ...

Nov 22, 2026

![Crystal Bio Solutions laboratory](https://www.crystalbiosolutions.com/hs-fs/hubfs/CBS%20lab/DSCF0117-min.jpg?width=320&height=240&name=DSCF0117-min.jpg) Scientific Publications by Crystal Bio Solutions Scientists Peer-reviewed publications by Crystal Bio Solutions scientists in bioanalysis, biomarkers, ADC characterization, and clinical pharmacology.

Nov 22, 2026

![Scientist reviewing pharmacokinetic modeling data](https://www.crystalbiosolutions.com/hs-fs/hubfs/AI-Generated%20Media/Images/Modern%20Lab%20Research%20with%20Pharmacokinetic%20Data%20Analysis.png?width=320&height=240&name=Modern%20Lab%20Research%20with%20Pharmacokinetic%20Data%20Analysis.png) Choosing Checkpoint Inhibitor Combinations Before the Trial: What QSP Modeling Adds How quantitative systems pharmacology (QSP) models use existing clinical data to compare checkpoint inhibitor combinations and sequences ...

Nov 22, 2026

![Researcher examining drug vials in a lab](https://www.crystalbiosolutions.com/hs-fs/hubfs/AI-Generated%20Media/Images/Researcher%20Analyzing%20Colorful%20Drug%20Vials%20In%20Sophisticated%20Lab.png?width=320&height=240&name=Researcher%20Analyzing%20Colorful%20Drug%20Vials%20In%20Sophisticated%20Lab.png) Pediatric Dosing With Little Pediatric Data: How Population PK and Exposure-Response Simulation Fill the Gap How population PK, allometric scaling, and exposure-response simulation can support pediatric dose selection when pediatric data are ...

Nov 22, 2026

![Structure of an antibody-drug conjugate](https://www.crystalbiosolutions.com/hs-fs/hubfs/ADC%20structure.png?width=320&height=240&name=ADC%20structure.png) FDA's Clinical Pharmacology Guidance for ADCs: What to Plan From First-in-Human Onward FDA's 2024 clinical pharmacology guidance for ADCs: which analytes to measure from first-in-human, dosing, exposure-response, organ ...

Nov 22, 2026

![Scientist analyzing ADC samples in the lab](https://www.crystalbiosolutions.com/hs-fs/hubfs/AI-Generated%20Media/Images/ADC%20Research%20Lab%20Analysis%20with%20Scientist%20and%20Advanced%20Equipment.png?width=320&height=240&name=ADC%20Research%20Lab%20Analysis%20with%20Scientist%20and%20Advanced%20Equipment.png) Bispecific ADCs: Can 1 + 1 Be Greater Than 2? How bispecific antibody-drug conjugates aim to improve ADC selectivity, internalization, and resistance, and the design challenges early ...

Nov 22, 2026

![Crystal Bio Solutions laboratory](https://www.crystalbiosolutions.com/hs-fs/hubfs/CBS%20lab/DSCF0117-min.jpg?width=320&height=240&name=DSCF0117-min.jpg) NK Cell Engagers: Next-Generation Immunotherapy and What Their Clinical Development Requires How NK cell engagers work, what early DF1001 data showed in HER2-expressing solid tumors, and key considerations for dose selection and ...

Nov 22, 2026

![Two scientists reviewing a document together](https://www.crystalbiosolutions.com/hs-fs/hubfs/website-assets/experts-collaborating-at-crystal-bio-solutions.png?width=320&height=240&name=experts-collaborating-at-crystal-bio-solutions.png) Regulatory Meetings with FDA, EMA, and China's CDE: A Side-by-Side Guide How formal meetings with FDA, EMA, and China's CDE compare: meeting types, when to request them, scheduling timelines, and fees.

Nov 22, 2026

![Immunogenicity assay testing](https://www.crystalbiosolutions.com/hs-fs/hubfs/nab-ada-immunogenicity-crystalbiosolutions.png?width=320&height=240&name=nab-ada-immunogenicity-crystalbiosolutions.png) Immunogenicity Risk Assessment for Biologics: Prediction, Detection, Mitigation, and Reporting A practical overview of immunogenicity risk for biologics: predicting risk, detecting ADA and NAb, setting cut points, managing clinical ...

Nov 22, 2026

![Inspecting a microplate for a cell-based assay](https://www.crystalbiosolutions.com/hs-fs/hubfs/Microplate%20Inspection%20for%20Customized%20Assay%20Analysis.webp?width=320&height=240&name=Microplate%20Inspection%20for%20Customized%20Assay%20Analysis.webp) In Vitro Cytokine Release Assays: Formats, Interpretation, and Limits How in vitro cytokine release assays (CRA) support first-in-human safety for immunomodulatory biologics: formats, readouts, controls, and ...

Nov 22, 2026

![Crystal Bio Solutions](https://www.crystalbiosolutions.com/hs-fs/hubfs/crystal-biosolutions.png?width=320&height=240&name=crystal-biosolutions.png) Integrated Summary of Immunogenicity (ISI): What It Contains and Why It Matters What an Integrated Summary of Immunogenicity (ISI) contains, where it sits in the CTD, and why starting it early helps biologics reach ...

Nov 21, 2026

![Scientist examining a sample in a laboratory](https://www.crystalbiosolutions.com/hs-fs/hubfs/Microplate%20Inspection%20for%20Customized%20Assay%20Analysis.webp?width=320&height=240&name=Microplate%20Inspection%20for%20Customized%20Assay%20Analysis.webp) Cell-Based NAb Assay Development: Choosing the Format and Managing Interference How to choose between cell-based and competitive ligand-binding NAb assays, design a cell-based NAb assay, and manage drug and matrix ...

Nov 21, 2026

![HPLC autosampler in the Crystal Bio Solutions laboratory](https://www.crystalbiosolutions.com/hs-fs/hubfs/CBS%20lab/DSCF0117-min.jpg?width=320&height=240&name=DSCF0117-min.jpg) Biosimilar Analytical Similarity by HRMS: What the Package Should Contain What a monoclonal antibody biosimilar's comparative analytical assessment should include, and where HRMS fits: structure, PTMs, glycans and ...

Nov 21, 2026

![LC-MS/MS system used for hybrid bioanalysis](https://www.crystalbiosolutions.com/hs-fs/hubfs/943fa2104ad62217d9c39af32900dc180e7b419feef8d39248e49151f55efcd6.jpg?width=320&height=240&name=943fa2104ad62217d9c39af32900dc180e7b419feef8d39248e49151f55efcd6.jpg) Hybrid LC-MS/MS for Large Molecule and ADC Bioanalysis When to choose hybrid (immunocapture) LC-MS/MS over a ligand-binding assay for antibody, bispecific and ADC PK, and how the method is built ...

Nov 21, 2026

![ADA and NAb immunogenicity assessment diagram](https://www.crystalbiosolutions.com/hs-fs/hubfs/nab-ada-immunogenicity-crystalbiosolutions.png?width=320&height=240&name=nab-ada-immunogenicity-crystalbiosolutions.png) NAb Assay Qualification vs. Validation: What Each Stage Requires How NAb assay development, qualification and validation differ: format choice, cut points, sensitivity, drug tolerance and what FDA and EMA ...

Oct 14, 2026

![Clinical Dose Optimization: From Phase 2 Dose Finding to FDA Project Optimus](https://www.crystalbiosolutions.com/hs-fs/hubfs/AI-Generated%20Media/Images/Researcher%20Analyzing%20Colorful%20Drug%20Vials%20In%20Sophisticated%20Lab.png?width=320&height=240&name=Researcher%20Analyzing%20Colorful%20Drug%20Vials%20In%20Sophisticated%20Lab.png) Clinical Dose Optimization: From Phase 2 Dose Finding to FDA Project Optimus Explore how PK–PD biomarkers, exposure–response modeling and fit-for-purpose bioanalysis support clinical dose optimization and FDA Project ...

Sep 14, 2026

![How to Choose a CRO for ADC Bioanalysis](https://www.crystalbiosolutions.com/hs-fs/hubfs/AI-Generated%20Media/Images/Modern%20Lab%20Analyzing%20ADCs%20with%20Mass%20Spectrometer%20and%20Data%20Visualizations.png?width=320&height=240&name=Modern%20Lab%20Analyzing%20ADCs%20with%20Mass%20Spectrometer%20and%20Data%20Visualizations.png) How to Choose a CRO for ADC Bioanalysis A checklist for choosing a bioanalytical CRO for ADC and PK studies: analyte coverage, LBA and LC-MS/MS platforms, GLP/GCLP status, and ...

Jul 28, 2026

![Population PK/PD Modeling That Starts With Better Bioanalysis](https://www.crystalbiosolutions.com/hs-fs/hubfs/AI-Generated%20Media/Images/Modern%20Lab%20Research%20with%20Pharmacokinetic%20Data%20Analysis.png?width=320&height=240&name=Modern%20Lab%20Research%20with%20Pharmacokinetic%20Data%20Analysis.png) Population PK/PD Modeling That Starts With Better Bioanalysis Discover how integrated bioanalysis, biomarkers, ADA assessment and Pop PK/PD modeling support Model-Informed Drug Development and biologic ...

Jul 14, 2026

![Diagram of a cysteine-conjugated IgG1 antibody-drug conjugate and its critical quality attributes: DAR distribution, unconjugated antibody (D0), free payload, aggregates and fragments, and charge variants](https://www.crystalbiosolutions.com/hs-fs/hubfs/website-assets/cbs-adc-critical-quality-attributes-diagram.png?width=320&height=240&name=cbs-adc-critical-quality-attributes-diagram.png) Critical Quality Attributes in Antibody-Drug Conjugates Learn the six critical quality attributes (CQAs) every ADC program should monitor and how analytical characterization supports successful ...

Jun 10, 2026

![ADC Bioanalysis: DAR Profiling and Stability Analysis](https://www.crystalbiosolutions.com/hs-fs/hubfs/AI-Generated%20Media/Images/ADC%20Research%20Lab%20Analysis%20with%20Scientist%20and%20Advanced%20Equipment.png?width=320&height=240&name=ADC%20Research%20Lab%20Analysis%20with%20Scientist%20and%20Advanced%20Equipment.png) ADC Bioanalysis: DAR Profiling and Stability Analysis Explore key strategies for ADC bioanalysis, including DAR characterization, payload stability, and LC-MS-based biotransformation studies.

Jun 2, 2026

![High-Resolution Mass Spectrometry (HRMS) in Biologics Characterization](https://www.crystalbiosolutions.com/hs-fs/hubfs/HRMS_1.png?width=320&height=240&name=HRMS_1.png) High-Resolution Mass Spectrometry (HRMS) in Biologics Characterization Discover how high-resolution mass spectrometry enhances biologics characterization, supporting critical analyses from peptide mapping to ...

Mar 23, 2026

![Antibody Glycosylation by Crystal Bio Solutions](https://www.crystalbiosolutions.com/hs-fs/hubfs/Antibody-Glycosylation-Crystal-Biosolutions.png?width=320&height=240&name=Antibody-Glycosylation-Crystal-Biosolutions.png) Antibody Glycosylation: FDA Requirements and Characterization Fc glycosylation controls antibody efficacy and safety. Learn what FDA expects for characterization, manufacturing and biosimilar ...

Feb 16, 2026

![Monoclonal Antibody Biosimilar Drug](https://www.crystalbiosolutions.com/hs-fs/hubfs/Biosimilar-drug-antibody-crystal-bio-solutions.png?width=320&height=240&name=Biosimilar-drug-antibody-crystal-bio-solutions.png) What Does the FDA Require to Approve a Monoclonal Antibody Biosimilar in 2026? What does the FDA require to approve a monoclonal antibody biosimilar in 2026? Analytical, PK, clinical, and immunogenicity evidence ...

Feb 4, 2026

![Common analytical gaps in biosimilar drugs](https://www.crystalbiosolutions.com/hs-fs/hubfs/Common%20analytical%20gaps%20in%20biosimilar%20drugs.png?width=320&height=240&name=Common%20analytical%20gaps%20in%20biosimilar%20drugs.png) The 6 Most Common Analytical Gaps in Biosimilar Programs (and How to Fix Them) Learn the six most common analytical gaps in biosimilar development, why regulators flag them, and how to fix them early to reduce ...

Feb 3, 2026

![Ye Gu and Billy Wu at Crystal Bio Solutions booth at WCBP](https://www.crystalbiosolutions.com/hs-fs/hubfs/Ye-Gu-Billy-Wu-Crystal-Bio-Solutions.jpg?width=320&height=240&name=Ye-Gu-Billy-Wu-Crystal-Bio-Solutions.jpg) WCBP 2026: Why Comparability Is a Challenge for Late-Stage Biopharma WCBP 2026 highlights why comparability is now the key late-stage challenge, from analytical CQA assessment to regulatory expectations and ...

Dec 15, 2025

![Overview of D0 species in ADCs](https://www.crystalbiosolutions.com/hs-fs/hubfs/Illustration%20of%20D0%20competing%20with%20ADC.png?width=320&height=240&name=Illustration%20of%20D0%20competing%20with%20ADC.png) Critical Quality Attribute D0 Impact in ADC Modality Overview of D0 species in ADCs, compete for target binding, reduce ADC potency, and how they are characterized analytically in development.

Nov 21, 2025

![Antibody Drug Conjugate](https://www.crystalbiosolutions.com/hs-fs/hubfs/Thumbnail-Crystal-Bio-Solutions.png?width=320&height=240&name=Thumbnail-Crystal-Bio-Solutions.png) Strategies for Antibody-Drug Conjugate Bioanalysis ADC bioanalysis must track the antibody, the payload and drug-to-antibody ratio changes in vivo. An overview of the two main analytical ...

Oct 9, 2025

![Case Study: Improving NAb Assay Sensitivity and Drug Tolerance by Optimizing MRD](https://www.crystalbiosolutions.com/hs-fs/hubfs/CS%20-%20Blog%20%20Thumbnail-2.png?width=320&height=240&name=CS%20-%20Blog%20%20Thumbnail-2.png) Improving NAb Assay Sensitivity and Drug Tolerance by Optimizing MRD Case study: changing the minimal required dilution from 1:4 to 1:2 in a competitive ligand-binding NAb assay improved sensitivity 4-fold ...

Sep 18, 2025

![Case Study: Representative Pooled Matrix Selection is Critical in ADA Assays](https://www.crystalbiosolutions.com/hs-fs/hubfs/6.png?width=320&height=240&name=6.png) Representative Pooled Matrix Selection Is Critical in ADA Assays Case study: switching to a pooled matrix representative of the individual study lots changed the ADA screening cut point from 1.03 to 1.11 ...

Sep 18, 2025

![A Generic LC-MS/MS Solution for ADC PK Bioanalysis](https://www.crystalbiosolutions.com/hs-fs/hubfs/LC-MS-MS-ADC-PK-Bioanalysis.png?width=320&height=240&name=LC-MS-MS-ADC-PK-Bioanalysis.png) A Generic LC-MS/MS Solution for ADC PK Bioanalysis Case study: a generic LC-MS/MS workflow quantifying total antibody, conjugated payload and free payload for ADC PK studies, with ...

Sep 18, 2025

![Case Study: An immunogenicity analysis strategy to reduce the interference of soluble target proteins](https://www.crystalbiosolutions.com/hs-fs/hubfs/9.png?width=320&height=240&name=9.png) An Immunogenicity Analysis Strategy to Reduce Interference from Soluble Target Proteins Case study: a target-specific blocking antibody removed false-positive ADA signals caused by soluble drug target in four of five serum ...

Sep 18, 2025

![Case Study: Receptor occupancy of antibody drug measured by FACS](https://www.crystalbiosolutions.com/hs-fs/hubfs/7.png?width=320&height=240&name=7.png) Receptor Occupancy of an Antibody Drug Measured by Flow Cytometry Case study: a flow cytometry PD-1 receptor occupancy assay in the occupied format with total receptor normalization, CV below 8% and 3-day ...

Sep 16, 2025

![A LC-MS/MS Method for Oligonucleotide PK Bioanalysis](https://www.crystalbiosolutions.com/hs-fs/hubfs/LC-MSMS-Oligonucleotide-PK-Bioanalysis.png?width=320&height=240&name=LC-MSMS-Oligonucleotide-PK-Bioanalysis.png) An LC-MS/MS Method for Oligonucleotide PK Bioanalysis Case study: a validated ion-pair LC-MS/MS method for oligonucleotide PK bioanalysis (2.00–2000 ng/mL, about 4.1 min per sample), applied in ...

Sep 16, 2025

![Case Study: Immunophenotyping to identify peripheral lymphocyte subsets](https://www.crystalbiosolutions.com/hs-fs/hubfs/4-1.png?width=320&height=240&name=4-1.png) Immunophenotyping to Identify Peripheral Lymphocyte Subsets Case study: a validated flow cytometry method that identifies CD4 and CD8 T-cell subsets and five NK-cell subsets to support clinical ...

Sep 16, 2025

![Crystal Bio Solution Case Study](https://www.crystalbiosolutions.com/hs-fs/hubfs/Improve-Drug-Tolerance-ADA-Assay.png?width=320&height=240&name=Improve-Drug-Tolerance-ADA-Assay.png) Sample Pretreatment Approaches to Improve Drug Tolerance in ADA Assays Case study: adding an acid dissociation–affinity capture step raised ADA assay drug tolerance to at least 8 µg/mL of drug at 100 ng/mL ...

Oct 12, 2026

![18th Annual Immunogenicity & Bioassay Summit](https://www.crystalbiosolutions.com/hs-fs/hubfs/AAPS%20%281126%20x%201126%20px%29%20%283%29.png?width=320&height=240&name=AAPS%20%281126%20x%201126%20px%29%20%283%29.png) 18th Annual Immunogenicity & Bioassay Summit Visit Crystal Bio Solutions at Booth #4, 18th Annual Immunogenicity & Bioassay Summit, to explore partnerships that advance biologics ...

Sep 9, 2026

![Meet CBS at OCT Southern California 2026](https://www.crystalbiosolutions.com/hs-fs/hubfs/Website%20Event%20Cover-SCal%20OCT%20%202026-1.png?width=320&height=240&name=Website%20Event%20Cover-SCal%20OCT%20%202026-1.png) Meet CBS at OCT Southern California 2026 Meet the Crystal Bio Solutions bioanalysis, biomarker and clinical pharmacology team at OCT Southern California 2026, Booth #67b.

Aug 19, 2026

![Crystal Bio Solutions Scientific Symposium & Reception](https://www.crystalbiosolutions.com/hs-fs/hubfs/e58a70bc-953e-4dbb-9df6-06c3e5ffbd2b-1.png?width=320&height=240&name=e58a70bc-953e-4dbb-9df6-06c3e5ffbd2b-1.png) Crystal Bio Solutions Scientific Symposium & Reception The CBS Scientific Symposium & Reception took place on October 13, 2026 in South San Francisco, with talks on bioanalysis, biomarkers ...

Jun 3, 2026

![Heading to BIO International Convention 2026 in San Diego?](https://www.crystalbiosolutions.com/hs-fs/hubfs/CBS%20at%20BIO%202026.jpg?width=320&height=240&name=CBS%20at%20BIO%202026.jpg) Heading to BIO International Convention 2026 in San Diego? Connect with Crystal Bio Solutions in San Diego to optimize your assay strategy, biomarkers, and regulatory compliance.

Feb 16, 2026

![San Diego Biotech Networking Event 2026: CMC and Development Discussions](https://www.crystalbiosolutions.com/hs-fs/hubfs/San%20Diego.png?width=320&height=240&name=San%20Diego.png) San Diego Biotech Networking Event 2026: CMC and Development Discussions Join Crystal Bio Solutions in San Diego for an informal biotech networking evening focused on CMC, bioanalysis and development strategy.

Jan 12, 2026

![Allan Cortes, new head of west coast business development at Crystal Bio Solutions](https://www.crystalbiosolutions.com/hs-fs/hubfs/crystal-biosolutions.png?width=320&height=240&name=crystal-biosolutions.png) Allan Cortes Joins CBS as Head of West Coast Business Development Allan Cortes joins Crystal Bio Solutions as Head of West Coast Business Development, bringing biotech and CRO business development ...

Dec 22, 2025

![Crystal Bio Solutions at WCBP 2026 Washington](https://www.crystalbiosolutions.com/hs-fs/hubfs/Crystal%20Bio%20Solutions%20at%20WCBP%202026%20Washington.jpg?width=320&height=240&name=Crystal%20Bio%20Solutions%20at%20WCBP%202026%20Washington.jpg) Meet Us at WCBP 2026: All Symposium Details Included Crystal Bio Solutions exhibited at WCBP 2026. What WCBP is, who attends, and why it matters for biologics CMC and analytical development.

Sep 17, 2025

![Dr. Lorin K. Roskos Appointed Chief Scientific Officer and Head of Quantitative Clinical Pharmacology](https://www.crystalbiosolutions.com/hs-fs/hubfs/Dr-Loris-Roskos-CSO-Crystal-Bio-Solutions.png?width=320&height=240&name=Dr-Loris-Roskos-CSO-Crystal-Bio-Solutions.png) Dr. Lorin K. Roskos Appointed Chief Scientific Officer and Head of Quantitative Clinical Pharmacology Dr. Lorin K. Roskos joins Crystal Bio Solutions as Chief Scientific Officer and Head of Quantitative Clinical Pharmacology, with 30+ years ...

![Crystal Bio Solutions logo (footer)](https://www.crystalbiosolutions.com/hubfs/Logo_CBS-%E7%AB%96%E7%89%88-%E5%8F%8D%E7%99%BD.png)

- [Our Services](https://www.crystalbiosolutions.com) 
    - [Bioanalysis & Biomarkers](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [Biologics CMC Analytical](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
    - [Regulatory Affairs](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)
- [Information](https://www.crystalbiosolutions.com/news-and-events) 
    - [About Us](https://www.crystalbiosolutions.com/about-us)
    - [Quality & Compliance](https://www.crystalbiosolutions.com/quality-and-compliance)
    - [News & Events](https://www.crystalbiosolutions.com/news-and-events)
    - [Case Studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study)
    - [Scientific Articles](https://www.crystalbiosolutions.com/news-and-events/tag/blog)
    - [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Contact](https://www.crystalbiosolutions.com/contact-us) 
    - [Email Us](mailto:cbs_bd@crystalpharmatech.com)
    - [Contact Form](https://www.crystalbiosolutions.com/contact-us)
    - [Our Locations](https://www.crystalbiosolutions.com/locations)
    - [Crystal Group](https://www.crystalbiosolutions.com/about-us#crystal-group) 
          - [Crystal Pharmatech](https://www.crystalpharmatech.com/)
          - [Crystal NAX](https://www.crystalnax.com/)

<https://www.linkedin.com/company/crystal-bio-solutions/> [Follow us on LinkedIn News, events and openings](https://www.linkedin.com/company/crystal-bio-solutions/)

- [Privacy Policy](https://www.crystalbiosolutions.com/policies/privacy-policy)
- [Terms of Service](https://www.crystalbiosolutions.com/policies/terms-of-service)

Copyright © 2026 Crystal Bio Solutions, Inc. All rights reserved.